SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Frédéric Chopin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrédéric Chopin
Date of birth1810-03-01
IdentifiersMRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845
Document date1838-03-20
AuthorMatthias Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Results visit: tuberculosis confirmed; infectious diseases consultation and start of treatment. [S]

History of Present Illness

Mr. Chopin returns three days after his first visit, masked and seen in an airborne infection isolation room, for his results; Dr. Kowalczyk-Grant of infectious diseases sees him the same morning. He has stayed at home with no students or visitors, and his lessons have moved online. His cough and night sweats are unchanged, and he has coughed up streaks of blood once since the first visit. His three sputum smears show acid-fast bacilli (2+, 2+, and 1+), and the nucleic acid amplification test on the first sample detected Mycobacterium tuberculosis complex with no rifampin resistance; molecular tests for isoniazid and fluoroquinolone resistance and the cultures are pending. The interferon-gamma release assay is positive, HIV is negative, hepatitis B surface antigen and core antibody are negative with surface antibody positive from vaccination, and hepatitis C antibody is negative. He was relieved to have a name for the illness and asked how long treatment lasts and when he can teach again. After the four-month and six-month regimens were explained, he chose the four-month regimen and took his first observed dose with a meal in the clinic. [S]

ElementDetail
ResultsSmears 2+, 2+, 1+; amplification test positive without rifampin resistance; IGRA positive; HIV negative; hepatitis B immune; hepatitis C negative
SymptomsCough, one more streak of blood, night sweats
DecisionFour-month rifapentine-moxifloxacin regimen, first dose today
IsolationAt home; lessons online

Review of Systems

SystemResultFinding
RespiratoryPositiveCough with morning sputum; one more streak of blood since the first visit; no breathlessness at rest
ConstitutionalPositiveNight sweats and evening fevers; poor appetite
MusculoskeletalNegativeNo tendon or joint pain
NeurologicalNegativeNo numbness or tingling; fine finger movements normal
PsychiatricPositiveAnxious and low, but relieved to know the diagnosis; no thoughts of suicide or self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses)Oral route1838-03-20 to 1838-07-16completedS
Moxifloxacin 400 mg tablet, one tablet daily400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours afterOral route1838-03-20 to 1838-07-16completedS
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeksOral route1838-03-20 to 1838-07-16completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg)Oral route1838-03-20 to 1838-05-14completedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1838-03-20 to 1838-07-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1838-03-20Body height170cmS
1838-03-20Body weight48.4kgS
1838-03-20Body mass index (BMI) [Ratio]16.7kg/m2S
1838-03-20Systolic blood pressure102mm[Hg]S
1838-03-20Diastolic blood pressure64mm[Hg]S
1838-03-20Heart rate98/minS
1838-03-20Respiratory rate18/minS
1838-03-20Body temperature37.6CelS
1838-03-20Oxygen saturation in Arterial blood by Pulse oximetry95%S

Physical Exam

Vital signs recorded on 1838-03-20; see the Vital Signs section. [S]

SystemFinding
GeneralThin and tired; weight 48.4 kg; temperature 37.6 °C, pulse 98; seen in an airborne infection isolation room with a respirator
RespiratoryCoarse crackles and bronchial breathing over the right upper zone; fine crackles at the left apex
AbdomenSoft; liver not enlarged
MusculoskeletalAchilles and wrist tendons non-tender, as a baseline before moxifloxacin
NeurologicalNormal light touch and vibration in the fingers and feet, as a baseline before isoniazid

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and cultureresolvedconfirmed R04.2S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit.
Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic.
Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsEvery visitCompleted todayCough, one more streak of blood, night sweats; no improvement yet before treatment
ExaminationWeight, with the pyrazinamide dose checked against the weight bandMonthlyCompleted today48.4 kg: pyrazinamide 1000 mg for the 40 to under 55 kg band
Medication safetyAdverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluidsEvery visitCompleted todayBaseline tendon and nerve examination normal; warning symptoms explained
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin)Up to dateBaseline ALT 18, AST 24, bilirubin 0.5, all normal; repeat ordered for the next visit
LaboratoryPotassium, calcium, magnesium, platelets, creatinineBaseline, then as indicatedUp to dateBaseline potassium 4.0, calcium 9.0, magnesium 2.0, platelets 442 (raised with inflammation), creatinine 0.78
Medication safetyElectrocardiogram (QT interval)Not routine; only if clinically indicatedNot indicatedNo QT history, no QT-prolonging medicines, normal potassium and magnesium
LaboratorySputum acid-fast smear and cultureBaseline, then monthly until two consecutive cultures are negativeCompleted todayThree baseline smears 2+, 2+, 1+; cultures pending
LaboratoryNucleic acid amplification test with rifampin resistanceAt baselineCompleted todayMycobacterium tuberculosis complex detected; rifampin resistance not detected
LaboratoryRapid molecular testing for isoniazid and fluoroquinolone resistanceAt baselineOrderedSent on the first sample; pending
LaboratoryPhenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin)At baselineOrderedOn the culture isolate when it grows
LaboratoryInterferon-gamma release assayAt baselineCompleted todayPositive; supports, but could not by itself prove or exclude, active tuberculosis
LaboratoryHIV testAt baselineCompleted todayHIV-1/2 antigen and antibody negative
LaboratoryHepatitis B and C serologyAt baselineCompleted todayHepatitis B surface antigen and core antibody negative, surface antibody positive (vaccinated); hepatitis C antibody negative
ImagingChest X-rayBaseline; at two months only if baseline cultures were negative; end of treatment optionalUp to dateRight upper lobe cavity on X-ray and CT at the first visit
Medication safetyDoses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months)Every visitCompleted todayVideo-observed therapy set up with the health department; first dose observed in clinic today
Medication safetyDrug interactions: rifapentine, and mineral products with moxifloxacinWith every new medicine or supplementCompleted todayNo other medicines; mineral products to be kept apart from moxifloxacin; orange urine and tears expected
Self-managementHome airborne isolation and the release criteriaUntil three negative smears, clinical improvement, and two weeks of treatmentCompleted todayContinues at home; lessons online
ReferralReport to the health departmentSame day as suspicion and on confirmationCompleted todaySuspected case reported at the first visit; confirmation sent today
ReferralContact investigation (students, friends, close contacts)Led by the health department from diagnosisReferredHealth department listing his students and other close contacts; their results are not part of his record
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentUp to date7 at the first visit, item 9 scored 0
Self-managementNutrition: dietitian, intake, supplement drinksEvery visit until weight is restoredOrderedFirst dietitian visit by video this week
LaboratorySweat chloride and serum alpha-1 antitrypsinOnce, to address the alternativesOrderedAdvised by infectious diseases; at the next visit, once he is out of isolation
ReferralInfectious diseases reviewAt diagnosis, at two months, and at the end of treatmentCompleted todaySeen today by Dr. Kowalczyk-Grant

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017); American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Release smears in the third week, then review at about two and a half weeks with liver tests, the sweat chloride test, and the alpha-1 antitrypsin level. Call the same day for hepatitis symptoms or tendon pain. Next scheduled visit 1838-04-07: two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for cystic fibrosis and alpha-1 antitrypsin deficiency. [S]